Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Market Cap
$3.50M
Return on Equity (ROE)
-89.85%
TTM Avg
30.83%
3Y Avg
-183.24%
5Y Avg
-146.59%
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
193.27%
3Y Avg
-10433.46%
5Y Avg
-6975.64%
Market Cap
$3.53M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.63M
Return on Equity (ROE)
-5.85%
TTM Avg
-5.85%
3Y Avg
-10.40%
5Y Avg
7.36%
Market Cap
$3.65M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$3.65M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$3.30M
Return on Equity (ROE)
-591.60%
TTM Avg
-213.16%
3Y Avg
-150.57%
5Y Avg
-4.48%
Market Cap
$3.28M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eocene Ltd. (EOCN) | $3.50M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | -89.85% | 30.83% | -183.24% | -146.59% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -40.20% | 193.27% | -10433.46% | -6975.64% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | -282.13% | -313.25% | -153.55% | -153.55% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | -5.85% | -5.85% | -10.40% | 7.36% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A | 5741.84% | 2797.55% | 1847.94% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | -591.60% | -213.16% | -150.57% | -4.48% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | -40.75% | -35.89% | -218.64% | -156.11% |
| MBody AI Ltd. (MBAI)vs › | $3.25M | 120.45% | 927.43% | 433.61% | 340.10% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
